Mtmh.Jk
MTMH.JK operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the production and distribution of pharmaceutical products.
Business. MTMH.JK operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the production and distribution of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
MTMH.JK operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the production and distribution of pharmaceutical products.
MTMH.JK has a debt-to-equity ratio of 0.52, indicating a moderate level of leverage, and a current ratio of 0.43, suggesting potential liquidity constraints. The company's free cash flow is negative at -136,575,320,380, which may signal pressure on liquidity and the need for external financing.
The company's profitability is reflected in a return on equity of 2.95% and a return on assets of 1.65%, both of which are below the industry median for healthcare facilities and services. This suggests that MTMH.JK is underperforming in terms of capital efficiency and asset utilization compared to its peers.
MTMH.JK's revenue is concentrated in the pharmaceuticals segment, with no disclosed geographic diversification. This concentration may expose the company to higher operational and market risks, particularly in the event of regulatory changes or supply chain disruptions.
The company's growth trajectory is mixed, with a negative free cash flow and capital expenditures of -352,162,320,420. While revenue has grown to 1,357,852,480,870, the negative cash flow from operations indicates that the company is not generating sufficient cash to sustain its operations without external financing.
The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could necessitate further financing. However, the dilution risk is low, indicating that the company is not expected to issue additional shares in the near term.
Recent financial filings and transcripts do not indicate any major events or strategic shifts for MTMH.JK. The company's financial performance and risk profile remain stable, with no significant changes reported in the latest disclosures.
- MTMH.JK has a moderate debt-to-equity ratio but faces liquidity constraints due to a low current ratio.
- The company's profitability metrics are below the industry median, indicating underperformance in capital efficiency.
- Revenue is concentrated in the pharmaceuticals segment, with no geographic diversification disclosed.
- The company's negative free cash flow and high capital expenditures suggest a need for external financing.
- Liquidity risk is medium, and dilution risk is low, with no significant events reported in recent filings.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- MTMH.JK Market data — financials · 2026-05-28